1stOncology™: Cancer Intelligence Service – Page 15645 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Cancer Prevention Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference

On November 21, 2017 Cancer Prevention Pharmaceuticals (CPP), a clinical stage biotechnology company, reported it will give a corporate presentation at the Piper Jaffray 29th Annual Healthcare Conference on November 28, 7:50-8:10 a.m. ET at the Lotte New York Palace in New York City (Track Seven: Kennedy 2, 4th floor) (Press release, Cancer Prevention Pharmaceuticals, NOV 21, 2017, http://canprevent.com/wp-content/uploads/2013/08/CPP-Piper-Jaffray-Conference-FINAL-2017-11-21.pdf [SID1234522220]). CPP CEO Jeff Jacob will give an update on the company’s pipeline including its lead Phase 3 drug CPP-1X/sul for treatment of familial adenomatous polyposis (FAP). CPP recently engaged Piper Jaffray to support its anticipated financing activities.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients. In June, an Independent Data Monitoring Committee (IDMC) recommended continuation of the Phase 3 trial following a planned interim futility analysis. In September, the U.S. Food and Drug Administration granted CPP-1X/sul "fast track" status, potentially speeding regulatory approval and commercialization.

In 2016 CPP signed a collaboration agreement with Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) that grants Sucampo the sole option to acquire an exclusive license to commercialize CPP-1X/sul in North America. Sucampo recently highlighted CPP-1X/sul during their 2017 R&D Day in New York City.

For more information on the FAP clinical trial (CPP FAP-310), please visit: View Source

Genomic Health to Present at the 29th Annual Piper Jaffray Healthcare Conference

On November 21, 2017 Genomic Health, Inc. (NASDAQ: GHDX) reported that it will present at the 29th Annual Piper Jaffray Healthcare Conference in New York City on Tuesday, November 28, 2017 at 10:30 a.m. Eastern Time (Press release, Genomic Health, NOV 21, 2017, View Source [SID1234522219]).

To access the live and subsequently archived webcast of the presentation, go to the Investor Relations section of the company’s web site at View Source Please connect to the web site at least 15 minutes prior to the presentation to allow for any software download that may be necessary. An archived replay will be available for three months beginning 24 hours after the live presentation.

Neurocrine Biosciences to Present at the 29th Annual Piper Jaffray Healthcare Conference

On November 21, 2017 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) reported that it will present at the 29th Annual Piper Jaffray Healthcare Conference at 12:00 p.m. ET on Tuesday, Nov. 28, 2017, in New York City (Press release, Neurocrine Biosciences, NOV 21, 2017, View Source;p=RssLanding&cat=news&id=2318193 [SID1234522213]). Timothy P. Coughlin, Vice President Finance of Neurocrine Biosciences, will present at the conference.

The live presentation will be webcast and may be accessed on the Company’s website at View Source A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.

Molecular Templates to Present at the 29th Annual Piper Jaffray Healthcare Conference

On November 21, 2017 Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in oncology, reported that Eric E. Poma, Ph.D., Chief Executive and Chief Scientific Officer, will provide a corporate overview at the 29th Annual Piper Jaffray Healthcare Conference, taking place November 28-29 at the Lotte New York Palace Hotel in New York City (Press release, Molecular Templates, NOV 21, 2017, View Source [SID1234522212]).

Molecular Templates Presentation Details
Date: Tuesday, November 28
Time: 9:30am Eastern Time
Location: Lotte New York Palace Hotel, Track 6, Kennedy 1 Room
Webcast: View Source;tp_key=3ce376224c

Kancera performs the second partial payment for the Fractalkine project

On November 21, 2017 Kancera reported that it performs the second partial payment for the Fractalkine project (Press release, Kancera, NOV 21, 2017, View Source;releaseID=1396141 [SID1234522211]). According to the agreement with Acturum Real Estate AB, the second partial payment for the Fractalkine project is due when the drug candidate KAND567 has been given to a certain number of subjects in the ongoing Phase Ia study.Therefore, Kancera announces that two millions of the company’s shares have been newly issued to Acturum Real Estate AB.

Kancera AB (publ) has previously announced the Board’s decision to acquire the Fractalkine project by Acturum Real Estate AB. Payment for the Fractalkine project takes place through a three-stage offset issue with a total of up to 6 million shares in Kancera AB, of which now 4 million shares have been paid. Partial payments are due as the project develops to certain milestones up to the start of the second clinical study.

About the Fractalkine project
KAND567 is an orally available small molecule that blocks CX3CR1, the Fractalkine receptor. Fractalkine is an immune-modulating factor, a so-called chemokine, which transmits signals via the CX3CR1 receptor, thereby controlling the function of immune cells and cancer cells. The levels of Fractalkine molecules and CX3CR1 receptors have been shown to be elevated in several inflammatory diseases, in cancer and in chronic pain conditions.

Kancera’s drug candidate KAND567 is the most advanced drug candidate against CX3CR1 and has been shown to be effective against inflammation and pain in multiple preclinical disease models.

In the healthy individual, Fractalkine and its receptor, CX3CR1, regulate migration of immune cells from the blood capillary wall into areas where the immune system is needed. Cancer cells use the same system (CX3CR1 and Fractalkine) to invade healthy organs and form metastases. In addition, the presence of Fractalkine has been associated with a lack of effect of immuno-oncological drugs. Therefore, Kancera evaluates how well KAND567 can stop tumor growth.

Animal studies show that Fractalkine’s receptor is not essential for survival and that important immune functions remain intact despite the lack of receptor. The basis for successful development of KAND567 lies in effectively addressing local inflammation while maintaining a healthy immune system.

In clinical trials, blocking of the Fractalkine system has been shown to have the desired effect against auto-immune diseases such as Crohn’s disease and rheumatoid arthritis in refractory patients. These studies have been conducted by the pharmaceutical company Eisai using a monoclonal antibody. The results of these studies indicate that the probability increases for the Kancera AB drug candidate KAND567 to achieve clinical and commercial success as the first small-molecule drug that works through the Fractalkine system to combat many common diseases.